FDA eases REMS labeling for Travere’s Filspari, reducing liver monitoring and removing embryo-fetal toxicity rules, with FSGS approval review ongoing.
FDA eases REMS labeling for Travere’s Filspari, reducing liver monitoring and removing embryo-fetal toxicity rules, with FSGS approval review ongoing.
Copyright © Louis Velazquez. All Rights Reserved.